Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generics Bulletin Originals

Set Alert for Originals

Set Alert for What's Next
What's Next?

What’s Next? Five Things To Look Out For In July

In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In June

In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In April

In April, four Humira (adalimumab) biosimilars are to be listed on Australia’s Pharmaceutical Benefits Scheme, while first-quarter financial reports will hit the market.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.

Approvals Biosimilars
See All

Set Alert for Interviews

Industry Ready To Embrace Digitalization, Says IGBA

IGBA chair Sudarshan Jain has indicated that "companies are undergoing the change towards digital health," in the second part of an exclusive interview with Generics Bulletin in which Jain and IGBA secretary general Suzette Kox talk about the pandemic-driven shift towards digitalization and computerization.

Digital Health Biosimilars

‘Everything Cannot Be Locally Produced,’ Says IGBA Chair

In an exclusive interview with Generics Bulletin, IGBA chair Sudarshan Jain said that a resilient and diversified supply chain is critical, but localized production may not be the answer to everything. IGBA secretary general Suzette Kox and Jain discussed key lessons to be learned from COVID-19, the IGBA’s focus on regulatory harmonization, and challenges in driving the adoption of generics, biosimilars and value-added medicines.

International Biosimilars

BGMA Chief Samuels Sees Boost From UK Biosimilars Pathway

In the second part of an exclusive interview with Generics Bulletin, BGMA chief executive Mark Samuels talks about the UK’s new biosimilars licensing pathway, future trade deals and IP, and efforts around repurposing generics, as well as looking ahead to how the UK’s vaccination program could reshape the COVID-19 pandemic.

United Kingdom Biosimilars

New BGMA Chief Battles Twin Pressures Of COVID And Brexit

When Mark Samuels took over leadership of the BGMA earlier this year, he was immediately forced to grapple with the twin pressures of Brexit and the COVID-19 pandemic. However, he tells Generics Bulletin in an exclusive interview, the UK off-patent industry has succeeded in maintaining supply against this difficult backdrop and deserves a more coherent government strategy to support the sector.

United Kingdom Brexit
See All

Set Alert for Pricewatch UK
Pricewatch UK

June Sees UK Ivabradine Prices More Than Treble

Ivabradine exhibited interesting pricing dynamics in the UK in June, with the average cost of the heart failure treatment more than trebling despite the lowest offer in the market remaining stable.

Market Intelligence Pricing Strategies

UK Gentamicin Prices Rocket Up In May

Gentamicin prices saw huge increases in the UK in May, with the average shooting up by almost 600%.

Market Intelligence Pricing Strategies

Etoricoxib Leads Biggest UK Price Rises In April

Etoricoxib led the steepest price rises for UK generics in April, with the non-steroidal anti-inflammatory drug seeing average prices almost double.

Market Intelligence Pricing Strategies

Multiple Molecules See UK Prices Double In March

Etoricoxib, letrozole and trimethoprim experienced triple-digit rises in their average UK trade prices in March, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies
See All